Literature DB >> 12860892

Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease.

Thorsten Reffelmann1, Robert A Kloner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12860892     DOI： 10.1161/01.CIR.0000081166.87607.E2

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  33 in total

1.  Sildenafil prevents indomethacin-induced gastropathy in rats: role of leukocyte adherence and gastric blood flow.

Authors:  Camila L Santos; Marcellus H L P Souza; Antoniella S Gomes; Henrique P Lemos; Armênio A Santos; Fernando Q Cunha; John L Wallace
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

Review 2.  [Medicinal vasoactive therapy of microcirculation disorders in rheumatoid arthritis].

Authors:  G Riemekasten; H Schulze-Koops
Journal:  Z Rheumatol       Date:  2005-03       Impact factor: 1.372

3.  Characterization of a catalytic ligand bridging metal ions in phosphodiesterases 4 and 5 by molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical calculations.

Authors:  Ying Xiong; Hai-Ting Lu; Yongjian Li; Guang-Fu Yang; Chang-Guo Zhan
Journal:  Biophys J       Date:  2006-09-01       Impact factor: 4.033

Review 4.  A review of pulmonary arterial hypertension: Part 2: Current and expected treatments.

Authors:  C T Gan; A Vonk Noordegraaf; K M J Marques; J G F Bronzwaer; P E Postmus; A Boonstra
Journal:  Neth Heart J       Date:  2004-08       Impact factor: 2.380

5.  Sildenafil therapy for pulmonary hypertension before and after pediatric congenital heart surgery.

Authors:  Gaetano Palma; Raffaele Giordano; Veronica Russolillo; Sabato Cioffi; Sergio Palumbo; Marco Mucerino; Vincenzo Poli; Carlo Vosa
Journal:  Tex Heart Inst J       Date:  2011

Review 6.  The emerging role for type 5 phosphodiesterase inhibition in heart failure.

Authors:  Gregory D Lewis; Marc J Semigran
Journal:  Curr Heart Fail Rep       Date:  2006-09

7.  Drug therapy: Sildenafil for post-operative pulmonary hypertension and Eisenmenger syndrome - A brief review of literature and survey of expert opinion.

Authors:  Balu Vaidyanathan
Journal:  Ann Pediatr Cardiol       Date:  2008-01

8.  Sildenafil reduces insulin-resistance in human endothelial cells.

Authors:  Caterina Mammi; Donatella Pastore; Marco F Lombardo; Francesca Ferrelli; Massimiliano Caprio; Claudia Consoli; Manfredi Tesauro; Lucia Gatta; Massimo Fini; Massimo Federici; Paolo Sbraccia; Giulia Donadel; Alfonso Bellia; Giuseppe M Rosano; Andrea Fabbri; Davide Lauro
Journal:  PLoS One       Date:  2011-01-28       Impact factor: 3.240

9.  Role of the NO/cGMP/K(ATP) pathway in the protective effects of sildenafil against ethanol-induced gastric damage in rats.

Authors:  J V R Medeiros; G G Gadelha; S J Lima; J A Garcia; P M G Soares; A A Santos; G A C Brito; R A Ribeiro; M H L P Souza
Journal:  Br J Pharmacol       Date:  2007-12-10       Impact factor: 8.739

10.  Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes.

Authors:  Manling Zhang; Norimichi Koitabashi; Takahiro Nagayama; Ryan Rambaran; Ning Feng; Eiki Takimoto; Trisha Koenke; Brian O'Rourke; Hunter C Champion; Michael T Crow; David A Kass
Journal:  Cell Signal       Date:  2008-08-26       Impact factor: 4.315
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.